Calvenza EIV/EHV (Canada)

Manufacturer: Boehringer

Equine Rhinopneumonitis-influenza Vaccine

Killed Virus

Veterinary Use Only

Calvenza EIV/EHV Indications

For the vaccination of healthy, susceptible horses 6 months of age or older, including pregnant mares, as an aid in the reduction of respiratory diseases caused by equine herpesvirus type 1 (EHV-1) and type 4 (EHV-4), and by equine influenza virus types A₂ North American and A₂ Eurasian.

Administration And Dosage

Shake well before use. Using aseptic technique, vaccinate horses intramuscularly with a 2 mL dose. Administer a second 2 mL dose intramuscularly in 3-4 weeks using a different injection site. Administer a third 2 mL dose in 3-4 weeks by either the intramuscular or intranasal route. Revaccinate annually and prior to anticipated exposure, by either the intramuscular or intranasal route.

Precautions

Store at 2-7°C. Protect from freezing. Use entire contents when first opened. Do not vaccinate within 21 days before slaughter. Anaphylactoid reactions may occur. Antidote: Epinephrine.

Preservative

Gentamicin.

Manufactured By: Boehringer Ingelheim Vetmedica, Inc., St. Joseph, Missouri 64506 U.s.a.

U.s. Veterinary License No. 124

Manufactured For: Boehringer Ingelheim (canada) Ltd., Burlington, Ontario L7l 5h4

2 mL syringe	32607-00
10 Doses/20 mL	32606-00

Nac No.

12300454